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SBTAbstract Introduction: Mechanical ventilation (MV) weaning trial can be compared to a cardiac
stress test where spontaneous ventilation is a form of an exercise and therefore hemodynamic com-
promise can occur during the weaning process in critically ill patients. The combined increase in
arterial pressure and heart rate during unsuccessful weaning is quite suggestive of weaning failure
of cardiac origin. Assessment and prediction of weaning failure from cardiac origin remain compli-
cated in patients with chronic obstructive pulmonary disease (COPD). Recent data showed that
COPD itself is a powerful independent risk factor for cardiovascular morbidity and mortality, sug-
gesting that occult cardiac dysfunction could be frequent in patients with COPD. The immediate
transition from positive pressure mechanical ventilation to spontaneous ventilation may generate
signiﬁcant cardiopulmonary alterations that are complex and mainly include the inspiratory fall
in intrathoracic pressure, the increase in work of breathing, and the catecholamine discharge that
occur during abrupt transfer from mechanical ventilation to spontaneous breathing. Therefore, it
could be suggested that a treatment targeting the cardiovascular system decreasing the preload
might help the heart to tolerate the critical period of weaning more effectively.
Methods: This study was carried on 60 adult male and female patients admitted to the Critical
Care Medicine Departments in the Alexandria Main University Hospital and who fulﬁlled the diag-
nosis of acute exacerbation of COPD according to the Global initiative for chronic obstructive lung
disease (GOLD) [1], and considered eligible for weaning after at least 24 h of invasive mechanical
ventilation exhibiting systemic arterial hypertension during the start of spontaneous breathing trial.
30 of them were adult patients and served as the study group (Group I), and the other 30 were age-
matched adults who served as the control group (Group II). Each group was subjected to sponta-
neous breathing trial (SBT) using a T-piece receiving FiO2 the same as during mechanical ventila-
tion. Control group underwent SBT alone while the nitroglycerin group underwent continuous
nitroglycerin infusion started at the beginning of the SBT and titrated to maintain normal arterial
970 M.S. Atta et al.systolic blood pressure that is; 120–139 mmHg). Hemodynamic, oxygenation and respiratory mea-
surements were performed on the start of SBT, and after a 2-h T-piece SBT.
Results: Compared to the start of SBT, systolic arterial blood pressure and mean arterial blood
pressure decreased [from (Mean ± SD) 150.33 ± 14.26, 112.56 ± 9.37 mmHg to 134.33 ± 11.04,
92.78 ± 5.81 mmHg, respectively] in the nitroglycerin group, while the opposite occurred in the
control group as systolic arterial blood pressure and mean arterial blood pressure increased [from
(Mean ± SD) 144.67 ± 13.58, 109.78 ± 10.09 mmHg to 158.0 ± 19.43, 114.73 ± 10.82 mmHg,
respectively]. Mixed central venous saturation (ScvO2) decreased signiﬁcantly in the control group
at the end of SBT [from (Mean ± SD) 71.90 ± 1.84 to 69.25 ± 2.20%], while in the nitroglycerin
group, ScvO2 did not change at the end in comparison to the start of SBT [from (Mean ± SD)
71.63 ± 1.75 to 71.12 ± 1.65%]. Nitroglycerin infusion at the start of SBT enabled a successful
weaning from mechanical ventilation in 90% of patients in comparison to a successful weaning
from mechanical ventilation of only 63.3% in the control group.
Conclusions: Nitroglycerin infusion might facilitate the weaning off hypertensive COPD patients
by alleviating the cardiovascular compromise occurring during liberation from MV.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
The worldwide chronic obstructive pulmonary disease
(COPD) epidemic affects nearly 600 million people and
accounts for more than 2.2 million deaths each year [1]. COPD
is the fourth leading cause of death in the United States and is
the only common chronic illness for which mortality rates con-
tinue to increase [2].
The Global Initiative for chronic obstructive lung disease
(GOLD) deﬁnes COPD [3] as follows: ‘‘Chronic obstructive
pulmonary disease (COPD) is a preventable and treatable dis-
ease with some signiﬁcant extra-pulmonary effects that may
contribute to the severity in individual patients. Its pulmonary
component is characterized by airﬂow limitation that is not
fully reversible. The airﬂow limitation is usually progressive
and associated with an abnormal inﬂammatory response of
the lungs to noxious particles or gases’’.
Airﬂow obstruction makes COPD an even greater health
burden because it independently contributes to the morbidity
and mortality of coexisting chronic conditions, such as ische-
mic heart disease and heart failure [4]. Airﬂow obstruction
and emphysema have been associated with impaired left ven-
tricular ﬁlling [5].
Periods of acute worsening of this disease are termed as
exacerbations. An exacerbation of COPD is deﬁned as ‘‘an
event in the nature course of the disease characterized by a
change in the patient’s baseline dyspnea, cough and/or sputum
that’s beyond normal day-to-day variation, is acute in onset,
and may warrant a change in regular medication in a patient
with underlying COPD’’ [3]. The principal identiﬁed causes
of COPD exacerbations include bacterial [6], and viral infec-
tions [7], pollution events [8,9], cold weather [10], and interrup-
tion of regular treatment [11].
Chronic obstructive pulmonary disease (COPD) is a com-
mon co-morbidity in patients with heart failure, and vice versa
‘‘strengthens the hypothesis that pulmonary obstruction itself
is a major risk factor for heart failure’’ [12]. The long-term risk
of developing heart failure increased with reduced lung func-
tion as measured by forced expiratory volume (FEV1) by spi-
rometry, ﬁndings which were not altered by age, prior heart
disease, or cardiovascular risk factors (including smoking) [13].Considerable negative intra-thoracic pressures developed at
inspiration during airway obstruction or pulmonary dynamic
hyperinﬂation or both increase venous return (that is, preload)
and also effectively increase left ventricular after load [14,15].
Such increases may not be tolerated by spontaneously breath-
ing patients with compromised heart function [14].
COPD is a powerful independent risk factor for cardiovas-
cular morbidity and mortality, suggesting that occult cardiac
dysfunction could be frequent in patients with COPD [16].
Weaning-induced acute cardiac dysfunction resulting in acute
pulmonary congestion is a known cause or cofactor of weaning
failure in predisposed COPD patients, particularly in those
with pre-existing cardiac disease [17–20].
In COPD patients without obvious cardiac disease, a spon-
taneous breathing trial induced a signiﬁcant left ventricular
ejection fraction reduction not explained by a myocardial con-
tractility decrease due to ischemia, thus implying a weaning-
induced increase in the after load [21]. This increase in left ven-
tricular after load should be higher in patients demonstrating
systemic arterial hypertension, which is quite frequent in
COPD patients during weaning failure [19,22].
Vasodilators decrease the pressure gradients for venous
return and right and left ventricular ejection and can affect left
ventricular performance in a manner similar to that of the
increased intra-thoracic pressure [21]. Venous dilation reduces
venous pressure and decreases ventricular preload. This
reduces ventricular stress wall and oxygen demand by the
heart, thereby enhancing the oxygen supply/demand ratio. A
reduction in preload (reduced diastolic wall stress) also helps
to improve subendocardial blood ﬂow [23].
The efﬁcacy of nitrates primarily arises from a decrease in
left ventricular preload, manifested by a fall in pulmonary cap-
illary wedge pressure, and from decreases in pulmonary artery,
right ventricular, and right atrial pressures. In addition, the
arterial-arteriolar dilating effects of nitroglycerin in congestive
heart failure may result in a decrease in left ventricular after
load or impedance to ejection, with a subsequent increase in
stroke volume and cardiac output [24].
Therefore, it could be suggested that a treatment targeting the
cardiovascular system decreasing the preload might help the
heart to tolerate the critical period of weaning more effectively.
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The aim of the present study was directed to study the impact
of using nitroglycerin infusion on weaning off mechanically
ventilated COPD patients.
Patients and methods
Patient selection
Chronic obstructive pulmonary disease (COPD) patients who
were admitted to The Critical Care Department in the Alexan-
dria Main University Hospital (AMUH) and had met the
inclusion criteria, intubated and mechanically ventilated
because of acute decompensation. COPD was diagnosed on
the basis of clinical history, arterial blood gases, chest radio-
graphic ﬁndings and hospital admissions. Informed written
consent was obtained from each patient’s close relative.
Approval for the study was obtained from the ethics commit-
tee of the faculty.
Inclusion criteria for study entry were the following: (a) The
underlying cause of acute decompensation of COPD had been
resolved and the patients were ready to wean by performing
spontaneous breathing trials. Criteria used for not attempting
such spontaneous breathing trials are those of evidence-based
guidelines for weaning and discontinuing ventilatory support:
facilitated by ACCP/AARC/ACCM [25]: (1) Tachypnea (fre-
quency of greater than 35 breaths per minute). (2) Arterial
hemoglobin oxygen saturation (SaO2) of less than 85–90%
on pulse oximetry. (3) Tachycardia (heart rate of greater than
120–140 beats per minute) or a sustained change in heart rate
of more than 20%. (4) Systolic arterial blood pressure of
greater than 180–200 mmHg or less than 90 mmHg. (5)
Arrhythmias. (6) Increased accessory muscle use, diaphoresis,
and onset or worsening of discomfort. (b) Patients exhibiting
systemic arterial hypertension, deﬁned as systolic arterial
blood pressure of at least 140 mmHg during mechanical venti-
lation and just before the start of spontaneous breathing trial.
Exclusion criteria were: (1) Pregnant female. (2) Occurrence of
unstable coronary episode (Acute myocardial infarction or
unstable angina. (3) Arterial systolic blood pressure
<120 mmHg. (4) Prior Sildenaﬁl use in the last 48 h [26].
Protocol
The study was carried on 60 patients of both sexes who were
intubated and mechanically ventilated because of acute decom-
pensation and were considered eligible for weaning, 30 of them
were adult patients and served as the study group (Group I),
and the other 30 were age-matched adults serving as the con-
trol group (Group II). Each group was subjected to SBT using
a T-piece receiving FiO2 the same as during mechanical
ventilation. The control group underwent SBT alone while
the nitroglycerin group underwent continuous nitroglycerin
infusion started at the beginning of the SBT and titrated to
maintain normal arterial systolic blood pressure that is;
120–139 mmHg). Whenever SBT failed, administration of
nitroglycerin was stopped at the time of resumption of
mechanical ventilation. In case of trial success, nitroglycerin
was gradually decreased and ceased during the subsequent
hours.Measurements
Once the selected 60 patients were considered eligible for the
study, they were evaluated as regards: (a) Hemodynamic vari-
ables including heart rate, respiratory rate, systolic and mean
arterial blood pressure. (b) Oxygenation including Partial pres-
sure of oxygen (PaO2), Fraction of inspired oxygen (FiO2),
Hypoxemic index (HI), Arterial oxygen saturation (SaO2)
and Central mixed venous pressure of oxygen (ScvO2). (c) Par-
tial pressure of carbon dioxide (PaCO2). (d) Arterial blood
acidity (pHa).
Weaning policy
Patients were placed in semi recumbent position while venti-
lated in the synchronized intermittent mechanical ventilation
(SIMV) mode with the ventilator settings prescribed by the pri-
mary physician. Patients underwent a spontaneous breathing
trial via a T-piece circuit while receiving the same FiO2 as dur-
ing mechanical ventilation and gas humidiﬁcation. Trials
lasted for 2 h unless patients had met the criteria used to deﬁne
spontaneous breathing trial failure as mentioned before. The
ability of the patient to remain free of these criteria at the
end of the trial was deﬁned as successful spontaneous breath-
ing trial, and the patient was extubated. Extubation was
deﬁned as successful when spontaneous breathing was sus-
tained for more than 48 consecutive hours after the T-piece
trial, without development of any of the criteria of weaning
failure. Patients who had met these criteria during the 2-h trial
or within 48 h after extubation, were put back on the synchro-
nized intermittent mechanical ventilation (SIMV) mode, and
weaning was deﬁned as spontaneous breathing trial failure or
extubation failure, respectively. Weaning failure or success
was judged by the primary physicians, who were not the study
investigators. After resumption of mechanical ventilation,
small-bolus infusions of propofol (0.5–1 mg/kg) were given if
required in weaning failure patients to achieve synchronization
with the ventilator, and patients were not disconnected from
the ventilator for the subsequent 24 h.
Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package version 20.0 [27,28]. Qualitative data were
described using number and percent. Quantitative data were
described using range (minimum and maximum), mean, stan-
dard deviation and median. Comparison between different
groups regarding categorical variables was tested using Chi-
square test. When more than 20% of the cells have expected
a count less than 5, correction for chi-square was conducted
using Fisher’s Exact test or Monte Carlo correction. The dis-
tributions of quantitative variables were tested for normality
using Kolmogorov–Smirnov test, Shapiro–Wilk test and
D’Agostino test, also Histogram and QQ plot were used for
vision test. If it reveals normal data distribution, parametric
tests were applied. If the data were abnormally distributed,
non-parametric tests were used. For normally distributed data,
comparison between the two studied groups was done using
independent t-test. Signiﬁcance test results are quoted as
two-tailed probabilities. Signiﬁcance of the obtained results
was judged at the 5% level.
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Figure 2 Comparison between the studied groups according to
sex.
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Group I and Group II were homogeneous in terms of size, and
demographic characteristics of the patients as shown in Table 1
and Figs. 1 and 2 with no statistically signiﬁcant difference
between them.
The effects of nitroglycerin on hemodynamics are shown in
Table 2 and Figs. 3 and 4. No signiﬁcant difference was
detected between Group I and Group II at the start of SBT.
From the start to the end of SBT, systolic arterial blood pres-
sure (SABP), and mean arterial blood pressure (MABP)
decreased in Group I [from (Mean ± SD) 150.33 ± 14.76,
112.56 ± 9.37mmHg to 134.33 ± 11.04, 92.78 ± 5.81 mmHg,
respectively] compared with Group II whereas, both of them
increased [from (Mean ± SD) 144.67 ± 13.58, 109.78 ±
10.09 mmHg to 158.0 ± 19.43, 114.73 ± 10.82 mmHg, respec-
tively] with statistically signiﬁcant difference between both
groups at the end of SBT (p< 0.001*).
The effects of nitroglycerin on oxygenation variables are
shown in Table 3 and Fig. 5. Oxygenation variables were similar
in Group I andGroup II at the start of SBT. During the sponta-
neous breathing trial, centralmixed venous saturation decreased
[from (Mean ± SD) 71.90 ± 1.84 to 69.25 ± 2.20%] in Group
II, but did not change in Group I.0
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Figure 1 Comparison between the studied groups according to
age.
Table 1 Comparison between Group I and Group II
according to demographic characteristics.
Group I (n= 40) Group II (n= 40) p
No. % No. %
Gender
Male 27 90.0 25 83.3 0.706
Female 3 10.0 5 16.7
Age
Min.–Max. 45.0–84.0 47.0–84.0
Mean ± SD 66.13 ± 9.0 67.23 ± 9.0 0.638
Median 66.0 67.0
p, value for comparing between the two groups; SD, standard
deviation.Tidal volume decreased throughout the spontaneous
breathing trial in both groups [from (Mean ± SD)
6.97 ± 0.70 ml/kg in Group I and 6.76 ± 0.47 ml/kg in Group
II at the start of spontaneous breathing trial to 5.47 ± 0.70
and 5.23 ± 0.49 ml/kg in Group I and Group II at the end
of spontaneous breathing trial, respectively], with no statisti-
cally signiﬁcant difference between Group I and Group II at
the end of the study (p= 0.117) Table 4.
In both groups, partial pressure of carbon dioxide (PaCO2)
and arterial blood acidity (pHa) increased slightly throughout
the spontaneous breathing trial [from (Mean ± SD)
59.77 ± 12.40 mmHg, and 7.40 ± 0.03 to 61.97 ±
19.17 mmHg, and 7.41 ± 0.0, in Group I, respectively], and
[from (Mean ± SD) 65.63 ± 11.62 mmHg, and 7.40 ± 0.03
to 67.40 ± 17.92 mmHg, and 7.39 ± 0.10, in Group II, respec-
tively], with no statistically difference of signiﬁcance between
both groups at end of the study Table 5.
Nitroglycerin administration enabled a successful
spontaneous breathing trial in 90% of patients in Group I,
compared with a successful breathing trial of only 63.3% in
Group II without nitroglycerin administration, with
statistically signiﬁcant difference between both groups at end
of the study (p= 0.015*) Table 6 and Fig. 6.
Discussion
Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic morbidity and mortality throughout the
world. COPD is the fourth leading cause of death in the world
[1], further increases in its prevalence and mortality can be pre-
dicted in the coming decades [29].
AECOPD is deﬁned as an event in the natural course of the
disease characterized by a change in the patient’s baseline
dyspnea, cough, and/or sputum that is beyond normal day-
to-day variations, is acute in onset, and may warrant a change
in regular medication in a patient with underlying COPD
[30,31].
The aim of the study is to evaluate the impact of using
nitroglycerin infusion on weaning off mechanically ventilated
COPD patients.
We conducted a prospective observational study on 60
adult male and female patients admitted to the Critical Care
Table 2 Comparison between Group I and Group II according to hemodynamics during spontaneous breathing trial.
Hemodynamics Group I (n= 30) Group II (n= 30) P
Start End Start End
HR (beats/minutes)
Minimum 63.0 69.0 62.0 71.0 0.140a
Maximum 105.0 125.0 99.0 118.0
Mean 84.40 95.40 80.27 93.07
SD 11.54 15.06 9.97 13.23 0.526b
Median 87.0 96.50 79.0 91.50
RR (cycles/minutes)
Minimum 17.0 23.0 16.0 24.0 0.741a
Maximum 26.0 35.0 25.0 33.0
Mean 21.33 28.60 21.13 29.47
SD 2.26 2.62 2.40 2.65 0.208b
Median 21.50 29.0 21.0 30.0
SABP(mmHg)
Minimum 120.0 120.0 120.0 130.0 0.120a
Maximum 180.0 160.0 170.0 210.0
Mean 150.3 134.3 144.7 158.0
SD 14.26 11.04 13.58 19.43 <0.001*,b
Median 150.0 130.0 145.0 155.0
MABP(mmHg)
Minimum 86.70 86.70 86.70 95.0 0.273a
Maximum 126.7 106.7 123.3 135.0
Mean 112.6 92.8 109.8 114.7
SD 9.37 5.81 10.09 10.82 <0.001*,b
Median 113.3 91.65 110.0 115.0
HR, heart rate; RR, respiratory rate; SABP, systolic arterial blood pressure; MABP, mean arterial blood pressure; p, value for comparing
between the two groups.
a p-value of comparison between both groups at the start of spontaneous breathing trial.
b p-value of comparison between both groups at the end of spontaneous breathing trial.
* Statistically signiﬁcant at p 6 0.05.
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Figure 3 Comparison between the studied groups according to
MABP during SBT.
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Figure 4 Comparison between the studied groups according to
SABP during SBT.
Impact of nitroglycerin infusion on COPD patients 973Medicine Departments in the Alexandria Main University
Hospital and who fulﬁlled the diagnosis of acute exacerbation
of COPD according to the Global initiative for chronic
obstructive lung disease (GOLD), and considered eligible for
weaning after at least 24 h of invasive mechanical ventilation
according to evidence-based guidelines for weaning and
discontinuing ventilatory support: facilitated by ACCP/AARC/ACCM [25], exhibiting systemic arterial hypertension
during the start of spontaneous breathing trial.
Weaning critically ill patients from mechanical ventilation
(MV) is a gradual and challenging process. Discontinuation
of MV should be considered when patient is able to follow
commands and maintain appropriate minute ventilation. In
addition, protective airway reﬂexes should be intact and
patient clinical status must have improved. In general,
Table 3 Comparison between Group I and Group II according to oxygenation variables during spontaneous breathing trial.
Oxygenation variables Group I (n= 30) Group II (n= 30) P
Start End Start End
PaO2 (mmHg)
Minimum 65.0 65.0 68.0 70.0 0.375a
Maximum 152.0 136.0 214.0 176.0
Mean 99.43 95.0 105.9 98.53
SD 22.31 19.27 32.52 23.25 0.524b
Median 95.10 95.0 95.50 93.50
FiO2
Minimum 0.28 0.28 0.28 0.28 0.939a
Maximum 0.40 0.40 0.40 0.40
Mean 0.32 0.32 0.32 0.32
SD 0.05 0.05 0.05 0.05 0.960b
Median 0.30 0.29 0.30 0.29
HI
Minimum 215.0 211.0 243.0 245.0 0.585a
Maximum 478.0 410.0 535.0 440.0
Mean 318.6 302.2 328.7 310.0
SD 80.27 54.05 61.73 47.79 0.556b
Median 298.5 283.0 312.0 311.5
SaO2 (%)
Minimum 92.0 90.0 92.0 88.0 0.506a
Maximum 99.0 97.0 99.70 92.0
Mean 96.70 93.73 97.07 89.90
SD 2.23 2.05 2.01 1.03 <0.001*,b
Median 97.0 94.0 98.0 90.0
ScvO2 (%)
Minimum 68.0 67.0 69.0 64.0 0.568a
Maximum 74.0 73.50 75.0 72.50
Mean 71.63 71.12 71.90 69.25
SD 1.75 1.65 1.84 2.20 <0.001*,b
Median 72.50 71.50 72.25 69.25
PaO2, partial pressure of oxygen; FiO2, fraction of inspired oxygen; HI, hypoxemic index; SaO2, arterial oxygen saturation; ScvO2, central mixed
oxygen saturation; p, p value for comparing between the two groups.
a p-value of comparison between both groups at the start of spontaneous breathing trial.
b p-value of comparison between both groups at the end of spontaneous breathing trial.
* Statistically signiﬁcant at p 6 0.05.
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Figure 5 Comparison between Group I and Group II according
to ScvO2 during spontaneous breathing trial.
974 M.S. Atta et al.mechanical weaning parameters are poor at predicting wean-
ing success because they do not take into account cardiac
reserves [32]. Both experimental and clinical data give convinc-ing evidence of acute cardiac dysfunction as the origin or a
cofactor of weaning failure.
Nitroglycerin is vasodilator agent that decreases the pres-
sure gradients for venous return and right and left ventricular
ejection and can affect left ventricular performance in a man-
ner similar to that of the increased intra-thoracic pressure.
Venous dilation reduces venous pressure and decreases ventric-
ular preload. This reduces ventricular stress wall and oxygen
demand by the heart, thereby enhancing the oxygen supply/
demand ratio. A reduction in preload (reduced diastolic wall
stress) also helps to improve subendocardial blood ﬂow [23].
MV weaning trial can be compared to a cardiac stress test
where spontaneous ventilation is a form of an exercise [32].
The immediate transition from positive pressure mechanical
ventilation to spontaneous ventilation may generate signiﬁcant
cardiopulmonary alterations that may not be tolerated by
spontaneously breathing patients with compromised heart
[33]. Furthermore, in COPD patients without obvious cardiac
disease, a SBT induced a signiﬁcant left ventricular ejection
fraction reduction implying a weaning-induced increase in
afterload [34]. This increase in left ventricular afterload should
Table 4 Comparison between Group I and Group II according to tidal volume (ml/kg) during spontaneous weaning trial.
Tidal Volume(ml/kg) Group I (n= 30) Group II (n= 30) P
Start End Start End
Minimum 5.50 4.0 6.30 4.60 0.177a
Maximum 8.50 7.0 8.20 6.70
Mean 6.97 5.47 6.76 5.23
SD 0.70 0.70 0.47 0.49 0.117b
Median 6.90 5.40 6.50 5.0
p, value for comparing between the two groups.
a p-value of comparison between both groups at the start of spontaneous breathing trial.
b p-value of comparison between both groups at the end of spontaneous breathing trial.
Table 5 Comparison between Group I and Group II accord-
ing to tidal volume (ml/kg) during spontaneous weaning trial.
Group I (n= 30) Group II (n= 30) P
Start End Start End
PaCO2 (mmHg)
Minimum 41.0 31.0 41.0 69.5 0.064a
Maximum 81.0 123.0 82.0 108.0
Mean 59.77 61.97 65.63 70.67
SD 12.40 19.17 11.62 15.65 0.061b
Median 57.50 58.0 66.0 69.50
pHa
Minimum 7.35 7.23 7.35 7.20 0.899a
Maximum 7.47 7.54 7.45 7.57
Mean 7.40 7.41 7.40 7.39
SD 0.03 0.08 0.03 0.10 0.478b
Median 7.40 7.43 7.40 7.41
p, value for comparing between the two groups.
a p-value of comparison between both groups at the start of
spontaneous breathing trial.
b p-value of comparison between both groups at the end of
spontaneous breathing trial.
Table 6 Comparison between Group I and Group II accord-
ing to tidal volume (ml/kg) during spontaneous weaning trial.
Group I (n= 30) Group II (n= 30) P
No. % No. %
Results
Successes 27 90.0 19 63.3 0.015*
Failed 3 10.0 11 36.7
p, value for comparing between the two groups.
* Statistically signiﬁcant at p 6 0.05.
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Figure 6 Comparison between the studied groups according to
results.
Impact of nitroglycerin infusion on COPD patients 975be higher in patients demonstrating systemic arterial hyperten-
sion [36,36].
In our study there was no signiﬁcant difference between the
two groups as regards demographic characteristic data, includ-
ing age, sex and smoking, among both groups.
In current study as regards hemodynamic variables, heart
rate increased throughout the study in both groups but with-
out signiﬁcant difference between both groups at end of the
study. Also, respiratory rate increased throughout the study
in both groups but without signiﬁcant difference between bothgroups at end of the study. In the nitroglycerin group, systemic
and mean arterial blood pressure decreased at the end of the
study. While in the control group, systemic and mean arterial
blood pressure did not change signiﬁcantly throughout the
study until the end.
In agreement with our study, Routsi et al. [37] conducted a
prospective interventional non-randomized study on twelve
difﬁcult-to-wean COPD patients who presented with systemic
arterial hypertension during weaning failure. Patients were
studied in two consecutive days, i.e., ﬁrst day without
nitroglycerin infusion (control day) and the second day with
nitroglycerin infusion started at the beginning of the SBT,
and titrated to maintain normal systolic blood pressure (study
day). Routsi et al. [37] demonstrated a slight increase in heart
rate and respiratory rate throughout the SBT until the end of
the study compared with mechanical ventilation on both
control and nitroglycerin days with (P= 0.26). Also, Routsi
et al. [37] demonstrated that from the start to the end of
SBT, mean and systemic arterial blood pressure increased
compared with mechanical ventilation on control day but
did not change on nitroglycerin day (P= 0.002 & <0.001),
respectively.
In current study as regards oxygenation, in the nitroglyc-
erin group, PaO2 decreased at the end of the study compared
to the beginning, however, there was no signiﬁcant difference
between the nitroglycerin and control groups at the end of
the study, however, it was not signiﬁcant (P= 0.872). There
976 M.S. Atta et al.was also no signiﬁcant difference between the two groups as
regards hypoxemic index.
In both groups, SaO2 decreased throughout the study but
with a signiﬁcant decrease in the control group. This decrease
can be attributed to multiple causes. First, a SBT induced a
signiﬁcant left ventricular ejection fraction reduction implying
a weaning-induced increase in after load [34] and this increase
in left ventricular after load should be higher in patients dem-
onstrating systemic arterial hypertension [35,36] thus leading
to left ventricular dysfunction and decreasing SaO2, however,
nitroglycerin infusion restored these changes leading to a
decrease in the after load of the heart and better toleration
of the critical period of weaning on the heart. Second, the sig-
niﬁcant decrease in SaO2 in the control group can be attributed
to a signiﬁcant decrease in ScvO2 among control group and
nitroglycerin infusion restored these changes by alleviating
acute cardiac dysfunction induced by weaning.
As regards central mixed venous saturation (ScvO2), ScvO2
decreased signiﬁcantly in the control group at the end of
SBT, while in the nitroglycerin group, ScvO2 did not change
at the end in comparison to the start of SBT resulting in a sig-
niﬁcant difference between both groups at the end of the study.
This decrease in ScvO2 in the control group and absence of any
change in the nitroglycerin group at end of the study can be
explained by weaning-induced acute cardiac dysfunction
resulting in acute pulmonary congestion that is a known cause
or cofactor of weaning failure in COPD patients [38].
Moreover, if oxygen consumption increased in healthy indi-
viduals cardiac output will increase to maintain the balance
between oxygen delivery and demand/consumption. But, in
the critically ill patients with inadequate cardiac reserve, the
response to an increase in oxygen consumption is restricted
to the patient’s ability to extract more of the available oxygen,
thus decreasing SvO2 [39]. Although the absolute values of Scv-
O2 and SvO2 differ, previous studies have shown close tracking
of the two measurements across a wide range of hemodynamic
conditions [40]. So decrease in SvO2 correlates with the
decrease in SvO2 and nitroglycerin infusion restored these
changes by alleviating acute cardiac dysfunction induced by
weaning.
In agreement with our study as regards oxygenation, Routsi
et al. [37] found the effects of nitroglycerin on oxygenation
variable were similar to control and study day. PaO2 decreased
from 132 ± 35 mmHg to 89 ± 23 mmHg in nitroglycerin day
and also PaO2 decreased from 130 ± 35 mmHg to
66 ± 17 mmHg at end of the study but there was not signiﬁ-
cant difference between both groups with (P= 0.23). Routsi
et al. [37] also found that during SBT, mixed venous saturation
decreased from 75.7 ± 3.5% with mechanical ventilation to
69.3 ± 7.5% on control day but did not change on the study
day with intravenous nitroglycerin infusion (P= 0.04).
In a similar study, Chick et al. [41], who studied the effect of
nitroglycerin on gas exchange, hemodynamic and oxygen
transport in patients with COPD, found that arterial PO2
slightly decreased about 2 mmHg following administration of
nitroglycerin however, this ﬁnding did not reach signiﬁcance.
In consistence with Chick et al., Kochukoshy et al. [42],
who also studied the effect of nitroglycerin in gas exchange
on patients with COPD, noted that there was slight decrease
in arterial oxygen tension for the duration of the study; the
maximal changes were from a mean pre-nitroglycerin value
of 53.5 mmHg to 50.3 mmHg at 30 min and also this valuefailed to reach a signiﬁcance. These ﬁndings were consistent
with previous study of Brent et al. who studied contrasting
acute effects of vasodilator (nitroglycerin, nitroprusside, and
hydralazine) on right ventricular performance in patients with
COPD and pulmonary hypertension.
In current study, tidal volume (VT/kg) decreased at end of
the study in both but without signiﬁcant difference between
both groups at the end of the study.
In agreement with our study, Routsi et al. [37] found that
tidal volume decreased throughout the SBT compared with
mechanical ventilation on both control day and nitroglycerin
day (P= 0.18).
In current study, Partial pressure of carbon dioxide (Pa-
CO2) was not signiﬁcantly changed in both groups at the end
of the study.
In agreement with our study, Routsi et al. [37] found that
PaCO2 slightly increased throughout the SBT compared with
mechanical ventilation on both control day and nitroglycerin
day but without signiﬁcant difference between both control
and nitroglycerin infusion (P= 0.18).
In current study, the arterial blood acidity (pHa) was not
signiﬁcantly changed in both groups at the end of the study.
In agreement with our study, Routsi et al. [37] found that
there was not signiﬁcantly change as regards the arterial blood
acidity (pHa) in comparison with mechanical ventilation on
both control day and nitroglycerin day with P= 0.20.
In the current study, as regards weaning success, there was
a signiﬁcant difference between both groups at the end of the
study with more success rate in the nitroglycerin group. At
the end of the study, all patients met the criteria of weaning
failure in both groups, had been put back on mechanical
ventilation, receiving small-bolus infusion of propofol
(0.5–1 mg/kg) to achieve synchronization with the ventilator
and were not disconnected from the ventilator for the
preceding 24 h and were excluded from the study.
In agreement with our study as regards weaning success,
Routsi et al. [37] noticed that on control day, all patients
met the criteria of weaning failure after 49 ± 33 min and were
returned to mechanical ventilation. In contrast, with nitroglyc-
erin infusion on the study day, 11 out of 12 patients (92%)
tolerated the spontaneous breathing trial (P> 0.001); one
patient failed this trial because of severe bronchospasm.
Similarly, Morley et al. [43] conducted a study to determine
if there was any short term hemodynamic improvement in
patients with stable severe COPD and cor pulmonale. They
found that the heart rate was increased by an infusion of nitro-
glycerin from a mean of 104 ± 16 before nitroglycerin to
113 ± 17 beats/min after nitroglycerin. Also PaO2 was not
signiﬁcantly changed by nitroglycerin administration from
49 ± 9 mmHg before nitroglycerin to 48 ± 10 mmHg after
nitroglycerin. The PaCO2 decreased slightly following
nitroglycerin administration from 54 ± 9 mmHg before nitro-
glycerin to 51 ± 10 mmHg after nitroglycerin. The mixed
venous oxygen tension decreased signiﬁcantly about 11% after
nitroglycerin infusion and was not accounted for by an
increase in oxygen delivery. Morley et al. suggested a reduction
in the cardiac output or worsening of ventilation–perfusion
relationships as a possible outcome. However, Morley et al.
failed to document strong correlation coefﬁcients between
the change in mixed venous oxygen tension and the change
in cardiac index. Morley et al. concluded that hemodynamic
testing would be required in individual patient to document
Impact of nitroglycerin infusion on COPD patients 977improved hemodynamic effects. Also, suggested that it may be
argued that the condition of patients without cor pulmonale
may be more responsive to vasodilator therapy.
Limitations of the study
The results of this study clearly showed that nitroglycerin infu-
sion can facilitate the weaning of hypertensive COPD patients,
yet the study had some limitations. First, the study was a sin-
gle-center study and the sample size was small and heteroge-
neous. Second the target of normal systolic arterial blood
pressure in the nitroglycerin group was achieved only partly
in some patients and their systolic blood pressure intermit-
tently remained higher than normal. Third, Swan Ganz cathe-
ter was not inserted to get the right atrial (RAP), pulmonary
artery (PAP), pulmonary artery occlusion (PAOP) pressures,
and cardiac index (CI) changes during nitroglycerin infusion.
Fourth, we could not assess the ventilation perfusion effects
of nitroglycerin infusion. Finally, this study was conducted
only on hypertensive COPD, and did not evaluate the effects
of nitroglycerin infusion in normotensive COPD patients.
Conclusion
Nitroglycerin infusion can facilitate the weaning off hyperten-
sive COPD patients by alleviating the cardiovascular compro-
mise occurring during liberation from MV.
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